The proteasome inhibitor PS-341 in cancer therapy

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2638-2645

  Teicher, Beverly A ^a,c   Ara, Gulshan ^a   Herbst, Roy ^a   Palombella, Vito J ^b   Adams, Julian ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ProScript Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOSENSITIVITY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; BREAST NEOPLASMS; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDES; DRUG SYNERGISM; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PROTEASE INHIBITORS; PYRAZINES; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; UBIQUITINS;

EID: 0032885416     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hilt, W., and Wolf, D. Proteasomes: destruction as a programme. Trends Biochem. Sci., 21: 96-102, 1996.
2. Maki, C., Huibregtse, J., and Howley, P. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res., 56: 2649-2654, 1996.
3. Yoshida, H., Kitamura, K., Tanaka, K., Omura, S., Miyazaki, T., Hachiya, T., Ohno, R., and Naoe, T. Accelerated degradation of PML-retinoic acid receptor a (PML-RARα) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res., 56: 2945-2948, 1996.
4. Rousset, R., Desbois, C., Bantignies, F., and Jalinot, P. Effects on NF-kB1/p105 processing of the interaction between the HTLV-1 trans-activator Tax and the proteasome. Nature (Lond.), 381: 328-331, 1996.
5. Mori, S., Tanaka, K., Omura, S., and Saito, Y. Degradation process of ligand-stimulated platelet-derived growth factor β-receptor involves ubiquitin-proteasome proteolytic pathway. J. Biol. Chem., 270: 29447-29452, 1995.
6. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell, 78: 773-785, 1994.
7. Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., and Riordan, J. R. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell, 83: 129-135, 1995.
8. Adams, J., and Stein, R. Novel inhibitors of the proteasome and their therapeutic use in inflammation. Ann. Rep. Med. Chem., 31: 279-288, 1996.
9. Kim, T., and Maniatis, T. Regulation of interferon-γ-activated STAT1 by the ubiquitin-proteasome pathway. Science (Washington DC), 273: 1717-1719, 1996.
10. Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A. L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78: 761-771, 1994.
11. Griscavage, J., Wilk, S., and Ignarro, L. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kB. Proc. Natl. Acad. Sci. USA, 93: 3308-3312, 1996.
12. 1 cyclin Cln2p by a Cdc34p-dependent pathway. EMBO J., 14: 303-312, 1995.
13. Yaglom, J., Goldberg, A., Finley, D., and Sherman, M. The molecular chaperone Ydj1 is required for the p34CDC28-dependent phosphorylation of the cyclin CIn3 that signals its degradation. Mol. Cell. Biol., 15: 3679-3684, 1996.
14. Seufert, W., Futcher, B., and Jentsch, S. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature (Lond.), 373: 78-81, 1995.
15. Ritcher-Ruoff, B., and Wolf, D. Proteasome and cell cycle. Evidence for a regulatory role of the protease on mitotic cyclins in yeast. FEBS Lett., 336: 34-36, 1993.
16. Fenteany, G., Standaert, R. F., Reichard, G. A., Corey, E. J., and Schreiber, S. L. A β-lactone related to lactacystin induces neunte outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc. Natl. Acad. Sci. USA, 91: 3358-3362, 1994.
17. Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., and Schreiber, S. L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (Washington DC), 268: 726-731, 1995.
18. Tanaka, H., Katagiri, M., Arima, S., Matsuzaki, K., Inokoshi, J., and Omura, S. Neuronal differentiation of neuro 2A cells by lactacystin and its partial inhibition by the protein phosphatase inhibitors calyculin A and okadaic acid. Biochem. Biophys. Res. Commun., 216: 291-297, 1995.
19. Iqbal, M., Chatterjee, S., Kauer, J., Das, M., Messina, P., Freed, B., Biazzo, W., and Siman, R. Potnet inhibitors of proteasome. J. Med. Chem., 38: 2276-2277, 1995.
20. Imajoh-Ohmi, S., Kawaguchi, T., Sugiyama, S., Tanaka, K., Omura, S., and Kikuchi, H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun., 217: 1070-1077, 1995.
21. Oda, K., Ikehara, Y., and Omura, S. Lactacystin, an inhibitor of the proteasome, blocks the degradation of a mutant precursor of glycosylphosphatidylinositol-linked protein in a pre-golgi compartment. Biochem. Biophys. Res. Commun., 219: 800-805, 1996.
22. Nagamitsu, T., Sunazuka, T., Tanaka, H., Omura, S., Sprengler, P., and Smith, A. B. I. Total synthesis of (+)-lactacystin. J. Am. Chem. Soc., 118: 3584-3590, 1996.
23. Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., and Elliott, P. J. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res., 59: 2615-2622, 1999.
24. Orlowski, R. Z., Eswara J. R., Lafond-Walker, A., Grever, M. R., Orlowski, M., and Dang, C. V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res, 58: 4342-4348, 1998.
25. Adams, J., Ma, Y., Stein, R., Baevsky, M., Grenier, L., and Plamondon, L. Boronic ester and acid compounds, synthesis and uses. US 1448.012TW01, 1996.
26. Shenvi, A. α-aminoboronic acid derivatives: effective inhibitors of aminopeptidases. Biochemistry, 25: 1286-1291, 1996.
27. Kettner, C., Mersinger, L., and Knabb, R. The selective inhibition of thrombin by peptides of boroarginine. J. Biol. Chem., 265: 18289-18297, 1990.
28. Soskel, N., Watanabe, S., Hardie, R., Shenvi, A., Punt, J., and Kettner, C. A new peptide boronic acid inhibitor of elastase-induced lung injury in hamsters. Am. Rev. Respir. Dis., 133: 639-642, 1986.
29. Snow, R., Bachovchin, W., Barton, R., Campbell, S., Coutts, S., Freeman, D., Guntheil, W., Kelly, T., Kennedy, C., Krolikowski, D., Leonard, S., Pargellis, C., Tong, L., and Adams, J. Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV: identification of a cyclin species containing a B-N bond. J. Am. Chem. Soc., 116: 10860-10869, 1994.
30. Kinder, D., Elstad, C., Meadows, G., and Ames, M. Antimetastatic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo. Invasion Metastasis, 72: 309-319, 1992.
31. Kelly, T., Adams, J., Bachovchin, W., Barton, R., Campbell, S., Coutts, S., Kennedy, C., and Snow, R. Immunosuppressive boronic acid dipeptides: correlation between conformation and activity. J. Am. Chem. Soc., 115: 12637-12638, 1993.
32. Frei, E., III, Holden, S. A., Gonin, R., Waxman, D. J., and Teicher, B. A. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemother. Pharmacol., 33: 113-122, 1993.
33. Teicher, B. A., Menon, K., Northey, D., Liu, J., Kufe, D. W., and Kaddurah-Daouk, R. Cyclocreatine in cancer chemotherapy. Cancer Chemother. Pharmacol., 35: 411-416, 1995.
34. Teicher, B. A., and Frei, E., III. Development of alkylating agent-resistant human tumor cell lines. Cancer Chemother. Pharmacol., 21: 292-298, 1988.
35. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y., Pfeffer, M. R., Crawford, J. M., and Frei, E., III. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (Washington DC), 247: 1457-1461, 1990.
36. Teicher, B. A., Chatterjee, D., Liu, J-T., Holden, S. A., and Ara, G. Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors. Cancer Chemother. Pharmacol., 32: 315-319, 1993.
37. Teicher, B. A., Holden, S. A., Ara, G., and Chen, G. Transforming growth factor-β in in vivo resistance. Cancer Chemother. Pharmacol., 37: 601-609, 1996.
38. Teicher, B. A., Holden, S. A., and Jacobs, J. L. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res., 47: 513-518, 1987.
39. Teicher, B. A., Alvarez Sotomayor, E., and Huang, Z. D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res., 52: 6702-6704, 1992.
40. Teicher, B. A., Holden, S. A., Ara, G., Alvarez Sotomayor, E., Huang, Z. D., Chen, Y.-N., and Brem, H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int. J. Cancer, 57: 920-925, 1994.
41. Lopes, U. G., Erhardt, P., Yao, R., and Cooper, G. M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem., 272: 12893-12896, 1997.